Journal article
Streptococcus pneumoniae serotype 33G: genetic, serological, and structural analysis of a new capsule type
Sam Manna, Joel P Werren, Belinda D Ortika, Barbara Bellich, Casey L Pell, Elissavet Nikolaou, Ilche Gjuroski, Stephanie Lo, Jason Hinds, Odgerel Tundev, Eileen M Dunne, Bradford D Gessner, Stephen D Bentley, Fiona M Russell, E Kim Mulholland, Tuya Mungun, Claire Von Mollendorf, Paul V Licciardi, Paola Cescutti, Neil Ravenscroft Show all
Microbiology spectrum | American Society for Microbiology | Published : 2024
Abstract
Streptococcus pneumoniae (the pneumococcus) is a human pathogen responsible for a spectrum of diseases such as pneumonia, sepsis, and meningitis. The capsule is the major pneumococcal virulence factor and is encoded by the capsular polysaccharide (cps) locus, a recombination hotspot that has resulted in over 100 distinct capsular polysaccharide types (serotypes) identified to date. Recently, 33X (also known as 10X) was proposed as a putative novel serotype, but the capsule structure had not been elucidated. Here, we provide an in-depth investigation of 33X, demonstrating it is a new pneumococcal capsular serotype. In this study, we screened 12,850 nasopharyngeal swabs from both healthy child..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council (NHMRC) Center of Research Excellence for Pneumococcal Disease Control in the Asia-Pacific
Awarded by Bill and Melinda Gates foundation
Awarded by Gavi Alliance
Awarded by MCRI
Awarded by Swiss National Science Foundation
Awarded by Bill and Melinda Gates Foundation
Funding Acknowledgements
This study was funded by a Robert Austrian Research Award in Pneumococcal Vaccinology awarded to SM by ISPPD (funded by Pfizer) and the National Health and Medical Research Council (NHMRC) Center of Research Excellence for Pneumococcal Disease Control in the Asia-Pacific (GNT1196415). The Mongolia carriage surveys and pneumonia surveillance programs were funded by the Bill and Melinda Gates foundation (Grant number OPP1115490), The Gavi Alliance (contract number PP61690717A2), and a Pfizer clinical research collaboration agreement with MCRI (contract number WI236621) for which MCRI was the study sponsor. Capsule structure work was funded by the Swiss National Science Foundation (Grant number 197083). The work at the Murdoch Children's Research Institute was also supported by the Victorian Government's Operational Infrastructure Support Program. Funders were neither involved in the collection and analysis of data nor in the decision to publish.